Vaqta vaccine market seen growing on hepatitis A demand
The Business Research Company says the Vaqta vaccine market is set for long-term growth through 2035, driven by rising hepatitis A cases, broader preventive vaccination efforts and higher health spending. North America led the market in 2025, while the report points to expansion opportunities in adult immunization and emerging markets.
Why it matters: - The Vaqta market is tied to broader demand for hepatitis A prevention as public health systems emphasize vaccines over treatment. - Growth in hepatitis A outbreaks, adult immunization programs and preventive care spending could expand vaccine adoption across multiple regions.
What happened: - The Business Research Company released its Vaqta Market Trends and Forecasts Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report forecasts long-term growth for the Vaqta vaccine market through 2035. - North America was the dominant Vaqta market region in 2025.
The details: - Vaqta is an inactivated vaccine designed to prevent hepatitis A, a contagious viral liver infection. - The vaccine is intended to trigger immune protection without causing the disease. - The report links historical market growth to routine immunization expansion, hepatitis A outbreaks, international travel, government vaccination campaigns and vaccine production improvements. - Future growth drivers include universal vaccination access, higher public health infrastructure spending, adult and elderly immunization programs, combination vaccine regimens and broader use in emerging markets. - The report identifies several trends shaping demand, including preventive vaccination efforts, travel-related immunization, adult vaccination coverage, better cold chain logistics and stronger public health education. - A free sample of the report is available here. - The full report is available here. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated technology and trend analysis.
Between the lines: - Rising hepatitis A infections are a direct demand signal for vaccines like Vaqta, especially in high-risk and outbreak-prone settings. - The report’s focus on adult and elderly vaccination suggests the market is broadening beyond childhood immunization programs. - Higher healthcare spending and stronger preventive care policy can make vaccine access less dependent on outbreak response alone. - The market thesis rests on public health systems treating vaccination as infrastructure, not just a reactive medical purchase.
What's next: - The report expects continued market expansion as vaccine access widens and preventive immunization becomes more common. - Emerging markets, travel medicine and adult vaccination campaigns are likely to remain key growth areas. - Ongoing hepatitis A surveillance and public health investment will help determine how quickly demand scales.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
World Politics Report
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.